Report overview
The global DPP-4 Inhibitor Hypoglycemic Drugs market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
Sitagliptin Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of DPP-4 Inhibitor Hypoglycemic Drugs include Merck, MSD Pharma, Novartis, AstraZeneca Pharmaceuticals, Takeda Pharmaceutical, Boehringer Ingelheim International, Huahai Pharmaceutical, Langnuo Pharmaceutical and QILU Pharmaceutical, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
DPP-4 inhibitor hypoglycemic drugs can not only reduce the blood sugar concentration of patients, but also promote insulin secretion, and even repair damaged islet cells. Compared with traditional hypoglycemic drugs, they have many advantages such as high efficacy and low side effects.
This report aims to provide a comprehensive presentation of the global market for DPP-4 Inhibitor Hypoglycemic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DPP-4 Inhibitor Hypoglycemic Drugs. This report contains market size and forecasts of DPP-4 Inhibitor Hypoglycemic Drugs in global, including the following market information:
Global DPP-4 Inhibitor Hypoglycemic Drugs Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global DPP-4 Inhibitor Hypoglycemic Drugs Market Sales, 2019-2024, 2025-2030, (K Units)
Global top five DPP-4 Inhibitor Hypoglycemic Drugs companies in 2023 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the DPP-4 Inhibitor Hypoglycemic Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global DPP-4 Inhibitor Hypoglycemic Drugs Market, by Type, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global DPP-4 Inhibitor Hypoglycemic Drugs Market Segment Percentages, by Type, 2023 (%)
Sitagliptin
Vildagliptin
Saxagliptin
Alogliptin
Linagliptin
Others
Global DPP-4 Inhibitor Hypoglycemic Drugs Market, by Application, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global DPP-4 Inhibitor Hypoglycemic Drugs Market Segment Percentages, by Application, 2023 (%)
Hospital
Clinic
Global DPP-4 Inhibitor Hypoglycemic Drugs Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global DPP-4 Inhibitor Hypoglycemic Drugs Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies DPP-4 Inhibitor Hypoglycemic Drugs revenues in global market, 2019-2024 (Estimated), ($ millions)
Key companies DPP-4 Inhibitor Hypoglycemic Drugs revenues share in global market, 2023 (%)
Key companies DPP-4 Inhibitor Hypoglycemic Drugs sales in global market, 2019-2024 (Estimated), (K Units)
Key companies DPP-4 Inhibitor Hypoglycemic Drugs sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
MSD Pharma
Novartis
AstraZeneca Pharmaceuticals
Takeda Pharmaceutical
Boehringer Ingelheim International
Huahai Pharmaceutical
Langnuo Pharmaceutical
QILU Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Gan & Lee Pharmaceuticals
Kelun Pharmaceutical
YOKO Pharmaceutical
Disainuo Pharmaceutical
Reyoung Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of DPP-4 Inhibitor Hypoglycemic Drugs, market overview.
Chapter 2: Global DPP-4 Inhibitor Hypoglycemic Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of DPP-4 Inhibitor Hypoglycemic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of DPP-4 Inhibitor Hypoglycemic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global DPP-4 Inhibitor Hypoglycemic Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
